Key Highlights
- XPEV shares declined more than 2% even as its inaugural IRON humanoid robot successfully completed automated assembly and walked independently from the production facility
- The company targets early 2027 for launching commercial IRON deployments across Chinese and international markets
- Over 80% of core manufacturing processes feature automation, utilizing technology borrowed from automotive production systems
- Dogotix, XPeng’s robotics division, secured $900 million in funding last month, pushing its valuation beyond $6.3 billion
- UBS launched coverage with a neutral stance and HK$47.00 price target, acknowledging robotics potential while highlighting EV business headwinds
XPeng’s inaugural IRON humanoid robot autonomously walked off the assembly line, yet the market response was muted. XPEV shares dropped approximately 2.2% on Wednesday to around $10.69, hovering near its 52-week bottom of $10.72. The stock has tumbled more than 40% since the beginning of the year.
This achievement signals XPeng’s transition from humanoid robot research and development into full-scale manufacturing. The robot successfully navigated through the automated final assembly sequence and departed the production line independently.
IRON features a biomimetic “bone-muscle-skin” framework incorporating a flexible spinal column, artificial muscles, soft synthetic skin covering its entire body, and hands with 22 degrees of freedom. The robot operates using a physical-world foundation model driven by three Turing AI processors.
The platform integrates visual perception, natural language processing, and movement capabilities through a multi-brain artificial intelligence framework. XPeng characterizes it as the “most human-like humanoid robot” in its portfolio.
XPeng’s internal team designed and constructed the production facility, implementing manufacturing and quality assurance systems derived from automotive industry practices. Automation accounts for more than 80% of critical production processes.
The company intends to launch commercial IRON deployments in domestic and international markets by the start of 2027. The robot will initially focus on hazardous and repetitive work assignments before expanding to wider use cases.
$900 Million Investment Round
In the previous month, Dogotix, XPeng’s robotics subsidiary, completed a $900 million private investment round. This financing established Dogotix’s valuation at more than $6.3 billion.
Bank of America reaffirmed its Buy recommendation with a $19.00 price objective following the fundraising disclosure.
UBS Launches Coverage
Coinciding with the production achievement, UBS began covering XPEV with a neutral recommendation and an HK$47.00 price objective. Analyst Paul Gong noted XPeng ranks among the most aggressive robotics participants within China’s automotive sector.
UBS employed a sum-of-the-parts methodology, allocating 30% of total value to robotics operations. The firm recognized XPeng for establishing $4.3 billion in robotics value through its financing activities.
Nevertheless, UBS identified obstacles in the primary automotive business, highlighting fierce competition, supply chain complications, and brief product lifecycles. XPeng continues operating at a loss, recording a negative EPS of $0.48 across the trailing twelve months.
Revenue increased 25% to reach $11.1 billion, though the EV division has fallen short of market projections.
Other Wall Street analysts maintain more reserved positions. Freedom Broker reduced its price objective to $22.00, referencing soft demand and intensifying price wars in China. Barclays lowered its target to $14.00, highlighting flat to low-single-digit delivery growth projections for Q3 2026.
Bernstein SocGen preserved a Market Perform recommendation, revising its price objective to $18.00 following expanded losses.
During Q2, XPeng posted revenue of RMB 19.7 billion, representing an 8% year-over-year increase and 51.5% sequential growth. Gross margin surpassed consensus forecasts, though adjusted net profit fell short of Bloomberg projections.





